Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 67

1.

Hydrogen sulfide prodrugs-a review.

Zheng Y, Ji X, Ji K, Wang B.

Acta Pharm Sin B. 2015 Sep;5(5):367-77. doi: 10.1016/j.apsb.2015.06.004. Epub 2015 Aug 21. Review.

2.

Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities.

Katz JN, Smith SR, Collins JE, Solomon DH, Jordan JM, Hunter DJ, Suter LG, Yelin E, Paltiel AD, Losina E.

Osteoarthritis Cartilage. 2016 Mar;24(3):409-18. doi: 10.1016/j.joca.2015.10.006. Epub 2015 Oct 23.

PMID:
26525846
3.

The Helicobacter Eradication Aspirin Trial (HEAT): A Large Simple Randomised Controlled Trial Using Novel Methodology in Primary Care.

Dumbleton JS, Avery AJ, Coupland C, Hobbs FD, Kendrick D, Moore MV, Morris C, Rubin GP, Smith MD, Stevenson DJ, Hawkey CJ.

EBioMedicine. 2015 Jul 10;2(9):1200-4. doi: 10.1016/j.ebiom.2015.07.012. eCollection 2015 Sep.

4.

The cost-effectiveness of celecoxib versus non-steroidal anti-inflammatory drugs plus proton-pump inhibitors in the treatment of osteoarthritis in Saudi Arabia.

Nasef SA, Shaaban AA, Mould-Quevedo J, Ismail TA.

Health Econ Rev. 2015 Dec;5(1):53. doi: 10.1186/s13561-015-0053-7. Epub 2015 Jun 11.

5.

FXR antagonism of NSAIDs contributes to drug-induced liver injury identified by systems pharmacology approach.

Lu W, Cheng F, Jiang J, Zhang C, Deng X, Xu Z, Zou S, Shen X, Tang Y, Huang J.

Sci Rep. 2015 Jan 29;5:8114. doi: 10.1038/srep08114.

6.
7.

PharmGKB summary: ibuprofen pathways.

Mazaleuskaya LL, Theken KN, Gong L, Thorn CF, FitzGerald GA, Altman RB, Klein TE.

Pharmacogenet Genomics. 2015 Feb;25(2):96-106. doi: 10.1097/FPC.0000000000000113. No abstract available.

8.

Interaction between Helicobacter pylori infection, nonsteroidal anti-inflammatory drugs and/or low-dose aspirin use: old question new insights.

Sostres C, Gargallo CJ, Lanas A.

World J Gastroenterol. 2014 Jul 28;20(28):9439-50. doi: 10.3748/wjg.v20.i28.9439. Review.

9.

Hydrogen sulfide (H2S) releasing agents: chemistry and biological applications.

Zhao Y, Biggs TD, Xian M.

Chem Commun (Camb). 2014 Oct 14;50(80):11788-805. doi: 10.1039/c4cc00968a. Review.

10.

Ischaemic cardiovascular risk and prescription of non-steroidal anti-inflammatory drugs for musculoskeletal complaints.

Koffeman AR, Valkhoff VE, Jong GW, Warlé-van Herwaarden MF, Bindels PJ, Sturkenboom MC, Luijsterburg PA, Bierma-Zeinstra SM.

Scand J Prim Health Care. 2014 Jun;32(2):90-8. doi: 10.3109/02813432.2014.929810. Epub 2014 Jun 15.

11.

Role of selective cyclooxygenase-2 inhibitors in exacerbation of inflammatory bowel disease: A systematic review and meta-analysis.

Miao XP, Ouyang Q, Li HY, Wen ZH, Zhang DK, Cui XY.

Curr Ther Res Clin Exp. 2008 Jun;69(3):181-91. doi: 10.1016/j.curtheres.2008.06.009.

12.

Testing cardiovascular drug safety and efficacy in randomized trials.

FitzGerald GA.

Circ Res. 2014 Mar 28;114(7):1156-61. doi: 10.1161/CIRCRESAHA.114.301809. Review.

13.

Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage.

Sostres C, Gargallo CJ, Lanas A.

Arthritis Res Ther. 2013;15 Suppl 3:S3. doi: 10.1186/ar4175. Epub 2013 Jul 24. Review.

14.

Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.

Coxib and traditional NSAID Trialists' (CNT) Collaboration, Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanas A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C.

Lancet. 2013 Aug 31;382(9894):769-79. doi: 10.1016/S0140-6736(13)60900-9. Epub 2013 May 30.

15.

Cyclo-oxygenase-2 inhibitors or nonselective NSAIDs plus gastroprotective agents: what to prescribe in daily clinical practice?

Masclee GM, Valkhoff VE, van Soest EM, Schade R, Mazzaglia G, Molokhia M, Trifirò G, Goldstein JL, Hernández-Díaz S, Kuipers EJ, Sturkenboom MC.

Aliment Pharmacol Ther. 2013 Jul;38(2):178-89. doi: 10.1111/apt.12348. Epub 2013 May 28.

16.

Efficacy and safety of short-term use of COX-2 inhibitors in patients after an acute stroke with musculoskeletal pain.

Rabadi MH, Rabadi FM, Hallford G, Aston CE.

Ann Indian Acad Neurol. 2013 Jan;16(1):47-52. doi: 10.4103/0972-2327.107699.

17.

Mechanisms, prevention and clinical implications of nonsteroidal anti-inflammatory drug-enteropathy.

Wallace JL.

World J Gastroenterol. 2013 Mar 28;19(12):1861-76. doi: 10.3748/wjg.v19.i12.1861. Review.

18.

GI-REASONS: a novel 6-month, prospective, randomized, open-label, blinded endpoint (PROBE) trial.

Cryer B, Li C, Simon LS, Singh G, Stillman MJ, Berger MF.

Am J Gastroenterol. 2013 Mar;108(3):392-400. doi: 10.1038/ajg.2012.467. Epub 2013 Feb 12.

19.

Pharmacogenomics in clinical practice and drug development.

Harper AR, Topol EJ.

Nat Biotechnol. 2012 Nov;30(11):1117-24. doi: 10.1038/nbt.2424. Epub 2012 Nov 8. Review. Erratum in: Nat Biotechnol. 2012 Dec;30(12):1249.

20.

Semi-mechanistic modeling of the interaction between the central and peripheral effects in the antinociceptive response to lumiracoxib in rats.

Vélez de Mendizábal N, Vásquez-Bahena D, Jiménez-Andrade JM, Ortiz MI, Castañeda-Hernández G, Trocóniz IF.

AAPS J. 2012 Dec;14(4):904-14. doi: 10.1208/s12248-012-9405-y. Epub 2012 Sep 12.

Items per page

Supplemental Content

Write to the Help Desk